American Century Companies Inc. Has $27.31 Million Stock Holdings in GSK PLC Sponsored ADR $GSK

Key Points

• American Century Companies Inc. increased its stake in GSK PLC by 8.0%, acquiring an additional 51,971 shares to own a total of 704,836 shares, valued at approximately $27.3 million.
• GSK reported $1.23 earnings per share for the recent quarter, exceeding the consensus estimate of $1.12, with revenues of $10.64 billion significantly above expectations.
• The company announced a quarterly dividend of $0.4206 per share, translating to an annualized dividend yield of 4.2%, despite recently cutting its dividend payout ratio to 77.78%.

American Century Companies Inc. boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 8.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 704,836 shares of the pharmaceutical company's stock after purchasing an additional 51,971 shares during the quarter. American Century Companies Inc.'s holdings in GSK were worth $27,305,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GSK. Voloridge Investment Management LLC increased its holdings in shares of GSK by 1,360.4% in the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after acquiring an additional 2,016,795 shares in the last quarter. Woodline Partners LP bought a new stake in shares of GSK in the fourth quarter worth about $36,665,000. Miller Howard Investments Inc. NY increased its holdings in shares of GSK by 138.4% in the first quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock worth $63,797,000 after acquiring an additional 955,891 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in shares of GSK by 68.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,237,034 shares of the pharmaceutical company's stock worth $75,656,000 after acquiring an additional 907,068 shares in the last quarter. Finally, Kahn Brothers Group Inc. bought a new stake in shares of GSK in the fourth quarter worth about $29,921,000. Institutional investors own 15.74% of the company's stock.

GSK Stock Up 0.4%

Shares of GSK stock traded up $0.15 on Wednesday, hitting $39.98. 2,324,504 shares of the stock were exchanged, compared to its average volume of 5,106,205. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of $81.43 billion, a P/E ratio of 18.52, a price-to-earnings-growth ratio of 1.72 and a beta of 0.51. The business has a 50-day moving average of $38.33 and a 200 day moving average of $38.16. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.26.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same period in the prior year, the firm posted $0.43 earnings per share. The business's quarterly revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK's dividend payout ratio is 77.78%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Six investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, GSK has a consensus rating of "Reduce" and a consensus price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.